AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Iteos Therapeutics Inc (NASDAQ:ITOS)
-- USD
0.000 0.000%Sponsored Reports
Loading...
| Previous Close (in USD) | -- |
|---|---|
| Change | 0.000 0.000% |
| 52 W H/L (in USD) | 18.750/8.200 |
| EBITDA (in USD) | -168.437M |
| PE Ratio | -- |
| Volume | -- |
| Diluted Eps TTM | -3.65 |
| Total Assets (in USD) | 667.588M |
|---|---|
| Total Liabilities (in USD) | 92.36M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 251.177M |
| Market Cap (in USD) | 616.979 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | 267.63M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Iteos Therapeutics Inc
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc"R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
321 Arsenal Street, Watertown, MA, United States, 02472
339 217 0161
Employees: 157
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Michel Detheux Ph.D. | Pres, CEO & Director | 1966 |
| 2. | Mr. Matthew A. Call M.B.A. | Chief Operating Officer | 1973 |
| 3. | Dr. Joanne Jenkins-Lager M.D. | Chief Medical Officer | 1972 |
| 4. | Mr. Matthew Gall | Chief Financial Officer | 1977 |
| 5. | Dr. Yvonne McGrath Ph.D. | Chief Scientific Officer | 1974 |
| 6. | Mr. Ryan Baker | Head of Investor Relations | NA |
| 7. | Mr. Phillipe Brantegem | Vice-Pres of HR | NA |
| 8. | Dr. Michel Detheux Ph.D. | President, CEO & Director | 1967 |
| 9. | Mr. Matthew Gall | Chief Financial Officer | 1978 |
| 10. | Ms. Adi Osovsky | VP & Head of Legal | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.920 2.144% | 42.715 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.750 1.734% | 42.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+3.250 0.765% | 420.63 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+16.030 2.659% | 600.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | 148.736M | 256.464M | -38.09M | -22.335M | -18.046M |
| Minority Interest | - | - | - | - | - |
| Net Income | 96.652M | 214.521M | -38.033M | -22.454M | -18.057M |
| Selling General Administrative | 43.947M | 40.505M | 15.34M | 8.837M | 4.312M |
| Gross Profit | 267.63M | 344.775M | - | - | - |
| Reconciled Depreciation | 0.803M | 0.603M | 0.535M | 0.611M | 0.505M |
| Ebit | 126.324M | 244.901M | -45.24M | -28.048M | -17.98M |
| Ebitda | 130.39M | 255.685M | -38.772M | -21.724M | -17.475M |
| Depreciation And Amortization | 4.066M | 10.784M | 6.468M | 6.324M | 0.505M |
| Operating Income | 126.324M | 244.901M | -45.24M | -28.048M | -21.501M |
| Other Operating Expenses | 138.043M | 89.693M | 39.307M | 23.269M | 17.817M |
| Interest Expense | -19.149M | 1.382M | 1.217M | 0M | 0.066M |
| Tax Provision | 52.084M | 41.943M | -0.057M | 0.119M | 0.011M |
| Interest Income | 11.361M | - | - | - | 0.066M |
| Net Interest Income | 11.361M | - | - | 0M | -0.066M |
| Income Tax Expense | 52.084M | 41.943M | -0.057M | 0.119M | 0.011M |
| Total Revenue | 267.63M | 344.775M | 0M | 0M | 0M |
| Total Operating Expenses | 138.043M | 89.693M | 39.307M | 23.269M | 17.817M |
| Cost Of Revenue | - | - | - | - | - |
| Total Other Income Expense Net | 22.412M | 11.563M | 7.15M | 5.713M | -0.163M |
| Net Income From Continuing Ops | 96.652M | 214.521M | -38.033M | -22.454M | -18.057M |
| Net Income Applicable To Common Shares | 96.652M | 214.521M | -43.402M | -26.535M | -20.066M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 667.588M | 754.991M | 884.712M | 344.558M | 30.744M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 12.236M | 12.701M | 24.172M | 3.218M | 0.879M |
| Total Liab | 92.36M | 91.659M | 331.892M | 21.361M | 15.075M |
| Total Stockholder Equity | 575.228M | 663.332M | 552.82M | 323.197M | 15.669M |
| Other Current Liab | 25.407M | 19.727M | 17.157M | 7.486M | 5.4M |
| Common Stock | 0.036M | 0.036M | 0.035M | 0.035M | 0.001M |
| Capital Stock | 0.036M | 0.036M | 0.035M | 0.035M | 51.758M |
| Retained Earnings | 124.633M | 237.275M | 140.623M | -73.898M | -35.865M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 1.695M | 2.598M | 3.662M | 3.332M |
| Cash | 251.177M | 284.803M | 848.537M | 336.326M | 19.868M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 40.014M | 42M | 304.124M | 14.998M | 13.196M |
| Current Deferred Revenue | 2.063M | 13.775M | 281.052M | 4.486M | 2.36M |
| Net Debt | -245.119M | -280.13M | -843.196M | -336.326M | -19.868M |
| Short Term Debt | 1.251M | 0.836M | 0.77M | - | 4.262M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 6.058M | 4.673M | 5.341M | - | - |
| Other Stockholder Equity | 463.799M | 435.665M | 413.18M | 51.885M | 53.614M |
| Property Plant Equipment | - | 2.121M | 2.072M | 1.352M | 1.336M |
| Total Current Assets | 550.652M | 628.298M | 874.713M | 339.544M | 26.076M |
| Long Term Investments | 100.539M | 118.225M | - | - | - |
| Short Term Investments | 280.739M | 328.359M | - | - | - |
| Net Receivables | 6.5M | 2.435M | 12.09M | 0.325M | 5.329M |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | -10.086M | -0.325M | - |
| Accounts Payable | 11.293M | 7.662M | 5.145M | 3.026M | 1.174M |
| Accumulated Other Comprehensive Income | -13.24M | -9.644M | -1.018M | 0.617M | -0.224M |
| Non Currrent Assets Other | 5.665M | 1.695M | 2.598M | 3.662M | 3.332M |
| Non Current Assets Total | 116.936M | 126.693M | 9.999M | 5.014M | 4.668M |
| Capital Lease Obligations | 6.058M | 4.673M | 5.341M | - | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -445.004M | -1.242M | -0.377M | -0.926M | -0.299M |
| Total Cashflows From Investing Activities | -446.062M | -1.242M | -0.377M | -0.926M | -0.299M |
| Total Cash From Financing Activities | 1.984M | 3.659M | 340.339M | 22.539M | 23.508M |
| Net Income | 96.652M | 214.521M | -38.033M | -22.454M | -18.057M |
| Change In Cash | -563.797M | 512.381M | 316.464M | -2.064M | 3.237M |
| Begin Period Cash Flow | 848.835M | 336.454M | 19.99M | 22.054M | 18.817M |
| End Period Cash Flow | 285.038M | 848.835M | 336.454M | 19.99M | 22.054M |
| Total Cash From Operating Activities | -111.193M | 513.14M | -25.176M | -23.145M | -19.097M |
| Depreciation | 0.803M | 0.603M | 0.535M | 0.611M | 0.505M |
| Other Cashflows From Investing Activities | -0.12M | -0.061M | -0.021M | -0.205M | -0.073M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | -1.274M |
| Sale Purchase Of Stock | 0.925M | 2.943M | -0.332M | 0M | -0.226M |
| Other Cashflows From Financing Activities | 1.059M | 3.659M | 127.011M | 22.539M | 23.734M |
| Capital Expenditures | 0.938M | 1.181M | 0.356M | 0.721M | 0.226M |
| Change In Working Capital | -228.491M | 284.21M | 9.33M | -1.082M | -1.856M |
| Other Non Cash Items | -1.718M | 0.012M | -0.035M | -0.01M | 0.069M |
| Free Cash Flow | -112.131M | 511.959M | -25.532M | -23.866M | -19.323M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 794296 |
| 2. | iShares Russell 2000 ETF | 2 years ago | 593028 |
| 3. | BlackRock Advantage Small Cap Core Instl | 2 years ago | 405245 |
| 4. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 391052 |
| 5. | CREF Stock R1 | 2 years ago | 310700 |
| 6. | Econopolis Belgian Champions A EUR Dis | 2 years ago | 298257 |
| 7. | Fidelity Small Cap Index | 2 years ago | 252287 |
| 8. | Eagle Small Cap Core Inst'l | 2 years ago | 233584 |
| 9. | iShares Russell 2000 Value ETF | 2 years ago | 227745 |
| 10. | iShares Biotechnology ETF | 2 years ago | 209985 |
| 11. | State St Russell Sm/Mid Cp® Indx NL Cl C | 2 years ago | 163200 |
| 12. | Fidelity Extended Market Index | 2 years ago | 153833 |
| 13. | Goldman Sachs Small Cp Val Insghts Instl | 2 years ago | 143640 |
| 14. | DFA US Targeted Value I | 2 years ago | 143179 |
| 15. | Blackrock Russell 2000 Alpha Tilts Fd A | 2 years ago | 130539 |
| 16. | Schwab US Small-Cap ETF™ | 2 years ago | 125658 |
| 17. | Dimensional US Targeted Value ETF | 2 years ago | 111575 |
| 18. | Kennedy Micro Cap | 2 years ago | 109470 |
| 19. | State St Russell Sm Cap® Indx SL Cl I | 2 years ago | 93012 |
| 20. | Vanguard Russell 2000 ETF | 2 years ago | 92837 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | RA Capital Management, LLC | 2 years ago | 4417259 |
| 2. | BlackRock Inc | 2 years ago | 4261745 |
| 3. | Mpm Asset Management, LLC | 2 years ago | 2738785 |
| 4. | EcoR1 Capital, LLC | 2 years ago | 1999249 |
| 5. | Boxer Capital LLC | 2 years ago | 1804058 |
| 6. | MPM Oncology Impact Management LP | 2 years ago | 1745943 |
| 7. | Vanguard Group Inc | 2 years ago | 1500602 |
| 8. | Goldman Sachs Group Inc | 2 years ago | 1484136 |
| 9. | BRAIDWELL LP | 2 years ago | 1162374 |
| 10. | Morgan Stanley - Brokerage Accounts | 2 years ago | 1131493 |
| 11. | Millennium Management LLC | 2 years ago | 882981 |
| 12. | Dimensional Fund Advisors, Inc. | 2 years ago | 791170 |
| 13. | 683 Capital Management LLC | 2 years ago | 715000 |
| 14. | Renaissance Technologies Corp | 2 years ago | 698900 |
| 15. | Geode Capital Management, LLC | 2 years ago | 568860 |
| 16. | State Street Corporation | 2 years ago | 551555 |
| 17. | Jacobs Levy Equity Management, Inc. | 2 years ago | 504545 |
| 18. | Artal Group S A | 2 years ago | 400000 |
| 19. | Saturn V Capital Management LLC | 2 years ago | 387095 |
| 20. | Barclays PLC | 2 years ago | 312580 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...